AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges
Executive Summary
AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement
You may also be interested in...
AstraZeneca Settles Nexium Kickback Suit; Deals Prohibiting Authorized Generic Sales Alleged
AstraZeneca agreed to pay $7.9 million to resolve allegations it paid kickbacks to Medco Health Solutions for preferred formulary placement of Nexium.
CMS Targeting LTC Facility Overprescribing, Citing Antipsychotics
The Centers for Medicare and Medicaid Services is proposing a new Medicare requirement that consulting pharmacists serving long-term care facilities maintain independence from the facility to help avoid drug “overprescribing and overutilization.”
CMS Targeting LTC Facility Overprescribing, Citing Antipsychotics
The Centers for Medicare and Medicaid Services is proposing a new Medicare requirement that consulting pharmacists serving long-term care facilities maintain independence from the facility to help avoid drug “overprescribing and overutilization.”